Gossamer Bio Inc GOSS.OQ GOSS.O is expected to show a fall in quarterly revenue when it reports results on November 5 (estimated) for the period ending September 30 2025
The San Diego California-based company is expected to report a 33.2% decrease in revenue to $6.331 million from $9.48 million a year ago, according to the mean estimate from 8 analysts, based on LSEG data.
LSEG's mean analyst estimate for Gossamer Bio Inc is for a loss of 19 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Gossamer Bio Inc is $9.00, about 72.8% above its last closing price of $2.45
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -0.18 | -0.18 | -0.17 | Beat | 6.1 |
Mar. 31 2025 | -0.17 | -0.19 | -0.16 | Beat | 14.7 |
Dec. 31 2024 | -0.17 | -0.15 | Beat | 11.8 | |
Sep. 30 2024 | -0.12 | -0.15 | -0.14 | Beat | 5.3 |
Jun. 30 2024 | 0.31 | 0.23 | 0.22 | Missed | -3.9 |
Mar. 31 2024 | -0.19 | -0.19 | -0.19 | Met | -0.5 |
Dec. 31 2023 | -0.19 | -0.21 | -0.21 | Met | -1 |
Sep. 30 2023 | -0.24 | -0.26 | -0.21 | Beat | 17.8 |
This summary was machine generated November 3 at 22:41 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments